Amgen 386 for Recurrent Glioblastoma

NCT01290263 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

DRUG: Amgen 386
DRUG: Bevacizumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]